METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: ASSOCIATION WITH BODY MASS INDEX AND DISEASE SEVERITY
- 1Bukovinian State Medical University
Abstract
Whether body mass index (BMI) can meaningfully distinguish inflammatory bowel disease (IBD) patients with concomitant metabolic dysfunction-associated steatotic liver disease (MASLD) was examined in a retrospective hospital series. The analysis covered 400 records from 2023-2024 with verified ulcerative colitis or Crohns disease and sufficient information on anthropometry, liver status, and intestinal disease activity. Normal BMI was documented in 118 patients, 176 were overweight, and 106 had obesity. MASLD classification required documented hepatic steatosis in the appropriate cardiometabolic setting; ultrasonography provided the principal evidence of steatosis, while laboratory findings, non-invasive indices, and elastography were considered when available. Ulcerative colitis activity was based on the Mayo Score and Crohns disease activity on CDAI. Overall, 181 patients (45.3%) met MASLD criteria. The corresponding frequencies across the three BMI strata were 20.3%, 49.4%, and 66.0% ({chi}2=49.29; p<0.001). Severe IBD was recorded in 6.8%, 14.8%, and 32.1%, respectively ({chi}2=39.45; p<0.001). Relative to normal BMI, the unadjusted odds of MASLD were 3.83-fold higher with overweight (95% CI 2.24-6.55) and 7.62-fold higher with obesity (95% CI 4.17-13.91). Thus, BMI categories identified groups with distinctly different burdens of both MASLD and severe IBD. Because treatment exposure, disease duration, and other covariates were not included in an adjusted model, the observed differences should be interpreted as associations rather than causal effects.
Related
- Monocyte-to-high-density lipoprotein cholesterol ratio and carotid atherosclerosis in patients with metabolic dysfunction-associated steatotic liver disease: a comparative analysis of systemic inflammatory indices.
- Association of the nutritional metabolic risk index with metabolic dysfunction-associated steatotic liver disease in a sub-plateau population
- Association between grip strength and cause-specific mortality in metabolic dysfunction-associated steatotic liver disease
- Association of longitudinal serum 25-hydroxyvitamin D trajectories with subsequent liver stiffness increase in patients with early-onset type 2 diabetes and metabolic dysfunction-associated steatotic liver disease
- Association between vitamin D deficiency and liver fibrosis assessed by transient elastography in patients with metabolic dysfunction-associated steatotic liver disease.
BibTeX
@misc{antoniv2026metabolic,
title = {{METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: ASSOCIATION WITH BODY MASS INDEX AND DISEASE SEVERITY}},
author = {A. Antoniv and N. Antoniv},
howpublished = {medRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.12.26365296},
url = {https://www.medrxiv.org/content/10.64898/2026.10.12.26365296v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: ASSOCIATION WITH BODY MASS INDEX AND DISEASE SEVERITY
AU - A. Antoniv
AU - N. Antoniv
PY - 2026
DA - 2026/10/12
PB - medRxiv
DO - 10.64898/2026.10.12.26365296
UR - https://www.medrxiv.org/content/10.64898/2026.10.12.26365296v1
AB - Whether body mass index (BMI) can meaningfully distinguish inflammatory bowel disease (IBD) patients with concomitant metabolic dysfunction-associated steatotic liver disease (MASLD) was examined in a retrospective hospital series. The analysis covered 400 records from 2023-2024 with verified ulcerative colitis or Crohns disease and sufficient information on anthropometry, liver status, and intestinal disease activity. Normal BMI was documented in 118 patients, 176 were overweight, and 106 had obesity. MASLD classification required documented hepatic steatosis in the appropriate cardiometabolic setting; ultrasonography provided the principal evidence of steatosis, while laboratory findings, non-invasive indices, and elastography were considered when available. Ulcerative colitis activity was based on the Mayo Score and Crohns disease activity on CDAI. Overall, 181 patients (45.3%) met MASLD criteria. The corresponding frequencies across the three BMI strata were 20.3%, 49.4%, and 66.0% ({chi}2=49.29; p<0.001). Severe IBD was recorded in 6.8%, 14.8%, and 32.1%, respectively ({chi}2=39.45; p<0.001). Relative to normal BMI, the unadjusted odds of MASLD were 3.83-fold higher with overweight (95% CI 2.24-6.55) and 7.62-fold higher with obesity (95% CI 4.17-13.91). Thus, BMI categories identified groups with distinctly different burdens of both MASLD and severe IBD. Because treatment exposure, disease duration, and other covariates were not included in an adjusted model, the observed differences should be interpreted as associations rather than causal effects.
ER -